Yep. Based on the interim results for Pfizer it makes you think buc results are marginal. Even if they are great, I doubt better than what was stated in the Pfizer PR. So, if parity or below the SP won’t move in the giant steps once hoped for.
Even from a revenue standpoint I wonder about the impact. Perhaps someone with more knowledge can I answer, but with Merck and Pfizer sales, do you really see doctors prescribing buc over them?
News 
Market Data 
Discover 
